Tumour angiogenesis and Ki‐67 expression in phaeochromocytoma

Ohji, Hiroshi; Sasagawa, Isoji; Iciyanagi, O.; Suzuki, Yoshitaka; Nakada, Teruhiro

doi:10.1046/j.1464-410x.2001.00102.x

Cited by 43 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although previous reports showed an increased proliferative activity in the central areas compared with the periphery of PTA (46), we found an even distribution of the vascular net through the entire gland. In addition, several studies performed in different endocrine tumors showed a lack of relationship between cell proliferation and angiogenesis (47)(48)(49). We did not find differences in the even distribution of blood vessels between different histological groups; thus, heterogeneity in vascularization between different regions of the gland is not likely to affect the results.…”

Section: Discussionmentioning

confidence: 41%

“…Another limitation of this study is that most of the so-called normal PTG are from patients with pHPT and are not strictly normal, because they are likely to be suppressed with respect to both secretory and proliferative activity compared with normal glands (46). However, we showed no relationship between vascularization and biochemical activity, and several studies in different endocrine tumors showed a lack of relationship between cell proliferation and angiogenesis (47)(48)(49); thus, we do not think the suppression of these normal glands influences the MVD. It is possible to hypothesize that angiogenesis, as in many other human cancers, plays a role in the progression of parathyroid carcinomas and that MVD and/or angiogenic growth factors could be used as a prognostic marker, or even further, as a potential therapeutic target.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions

Torre

Buley

Wass

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

Angiogenesis and lymphangiogenesis are involved in tumoral growth and metastatic spread. There is little information on angiogenesis and no available data on lymphangiogenesis in parathyroid glands (PTG). Using immunohistochemistry for CD34, LYVE-1 (specific markers for vascular and lymphatic endothelium, respectively), vascular endothelial growth factor (VEGF)-A, VEGF-C, and fibroblast growth factor (FGF)-2, this study analyzes microvascular density (MVD), lymphatic vascular density (LVD), and expression of angiogenic and lymphangiogenic growth factors in 13 normal PTG, 77 parathyroid adenomas (PTA), and 17 primary parathyroid hyperplasia (PPH). MVD was higher in PPH and PTA, compared with PTG (P < 0.001). There was no difference in VEGF-A expression among groups. In contrast, FGF-2 expression was higher in PPH, compared with PTA and PTG (P < 0.0001). FGF-2 scores and MVD were significantly correlated (r = 0.43). LVD did not differ among groups, and VEGF-C expression was unrelated to LVD. There was no relationship between MVD and tumor behavior (adenoma size, PTH, or calcium). In conclusion, this study shows increased angiogenesis in parathyroid proliferative lesions compared with normal glands and suggests that FGF-2 is proangiogenic in parathyroid tissue. In PTA, tumor behavior is not related to angiogenic phenotype. This is the first demonstration of lymphatic vessels in PTG, but the lack of correlation with VEGF-C expression suggests that VEGF-C is not the primary lymphangiogenic factor.

show abstract

Section: Discussionmentioning

confidence: 41%

Section: Discussionmentioning

confidence: 70%

Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions

Torre

Buley

Wass

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

“…The proliferation activity of tumour cells is a useful marker for estimating the growth potential in many tumours. Some authors have found a positive correlation between Ki-67 score (proliferation activity of the tumour) and malignant behaviour in pheochromocytomas [9,24,25,26]. However, the Ki-67 score is not a perfect tool: the score in most pheochromocytomas is low, between 0 and 2% [10,22,26].…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas – a comparative study

Białas¹,

Okoń²,

Dyduch³

et al. 2013

pjp

View full text Add to dashboard Cite

Pheochromocytomas are rare tumours with uncertain clinical behaviour. Histological separation between benign and malignant pheochromocytomas is usually difficult. The utilization of PASS criteria (Pheochromocytoma of the Adrenal Gland Scaled Score) has not provided a solid basis for separating benign from malignant tumours. The aim of this study was to investigate immunohistochemical markers (chromogranin, synaptophysin, S-100 and Ki-67) to find out if they could provide useful diagnostic and/or prognostic data in a series of 62 pheochromocytomas (5 cases followed an aggressive clinical course). Chromogranin and synaptophysin immunoreactivity proved to be diagnostically useful, allowing, together with the absence of immunoreactivity for inhibin and melan A, an unequivocal diagnosis of pheochromocytoma. The pattern of staining did not provide, however, significant prognostic information. The mean count of sustentacular S-100 positive cells was lower in malignant than in benign pheochromocytomas but the frequent architectural variability and the haemorrhagic and cystic changes make it very difficult to achieve a precise and reproducible count in the majority of tumours. Without questioning that the occurrence of metastases and/or recurrent disease still remains the only unquestionable criterion for diagnosing a malignant pheochromocytoma, we think that the combined use of the PASS score and Ki-67 index provides useful information for diagnosing malignancy.

show abstract

“…Feng [14], Zielke [15] and Roojens [25] have observed a significantly greater number of blood vessels in metastasizing tumors. However, other authors did not confirm these results [13,26,27].…”

Section: Resultsmentioning

confidence: 83%

Microvascular density and mast cells in benign and malignant pheochromocytomas

Białas¹,

Dyduch²,

Szpor³

et al. 2012

pjp

View full text Add to dashboard Cite

Pheochromocytomas, uncommon adrenal tumors, have an uncertain behavior. Recently, PASS criteria were proposed for differentiating between benign and malignant cases. These are not perfect, however. The aim of the study was to investigate angiogenesis and mast cell density in context of the clinical behavior and morphologic characteristics of pheochromocytomas. Mean intratumoral chymase positive cell count was 14.50 for malignant, 15.73 for benign cases; mean subcapsular chymase positive cell count was 12.50 for malignant, 11.27 for benign cases. Mean intratumoral tryptase positive cell count was 17.50 for malignant and 17.91 for benign cases; mean subcapsular tryptase positive cell count was 15.25 for malignant and 15.73 for benign cases. Mean intratumoral CD31 positive vessel count was 46.98 for malignant and 51.02 for benign cases; mean subcapsular CD31 positive vessel count was 44.86 for malignant and 39.81 for benign cases. Mean intratumoral CD105 positive vessel count was 37.84 for malignant and 35.95 for benign cases; mean subcapsular CD105 positive vessel count was 26.36 for malignant and 22.03 for benign cases. The differences between benign and malignant cases were not significant. All the vascular counts were correlated with mast cells counts. PASS index was inversely correlated with mast cell counts.

show abstract

Tumour angiogenesis and Ki‐67 expression in phaeochromocytoma

Cited by 43 publications

References 24 publications

Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions

Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions

Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas – a comparative study

Microvascular density and mast cells in benign and malignant pheochromocytomas

Contact Info

Product

Resources

About